Category : Search result: Novo Nordisk Eli Lilly


India's Drug Patent Wars: Need for Special Courts?

A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.

Lilly Singh: Women Aren't Funny? That's Dumb!

Exclusive interview with Lilly Singh on sisterhood, digital creators' respect, Hollywood diversity struggles, and why women comedians face unfair criticism. Read her powerful insights!

Alzheimer's Drug Donanemab Approved in India

Eli Lilly's Alzheimer's drug donanemab gets Indian regulatory approval. The treatment slows cognitive decline by 35.1% and could be available next year. Learn about its benefits and pricing.

Alzheimer's Drug Donanemab Approved for India

Eli Lilly's Alzheimer's drug donanemab gets Indian regulator nod. The treatment slows cognitive decline by 35.1% and is expected to launch in India next year. Details on pricing and safety.

European Pharma Stocks Rebound from AI Shift

European weight-loss drug makers surge as investors rotate capital from expensive AI stocks into healthcare. Zealand Pharma leads with a 20% weekly jump. Explore the market dynamics.

Novo Nordisk cuts Wegovy price 37% in India

Novo Nordisk reduces Wegovy price by 37% in India, intensifying the weight loss drug war with Eli Lilly's Mounjaro. Discover the new costs and market impact.

Novo Nordisk cuts Wegovy price 37% in India

Novo Nordisk reduces its weight loss drug Wegovy's price by 37% in India, intensifying competition with Eli Lilly's Mounjaro. Get the latest details on the new pricing and market dynamics.

Novo Nordisk cuts Wegovy price 37% in India

Novo Nordisk reduces Wegovy's price by 37% in India as it faces patent loss and competition from Eli Lilly's Mounjaro and upcoming generic versions. Discover the new costs.

Trump: Deal Reached to Lower Weight Loss Drug Prices

Former President Donald Trump reveals groundbreaking agreement with pharmaceutical giants to dramatically reduce costs of popular weight loss medications, promising relief for millions struggling with obesity.

Novo Nordisk Profit Drops 27%, Cuts 9,000 Jobs

Danish pharmaceutical giant Novo Nordisk faces turbulent times as Q3 profits drop 27% despite Ozempic's success. The company announces massive restructuring with 9,000 job cuts worldwide. Get the inside story on what's happening behind the scenes.

Trump's $149 Weight-Loss Drug Deal with Ozempic Maker

Former US President Donald Trump is negotiating with Novo Nordisk to offer weight-loss drugs at just $149. Discover how this could revolutionize affordable healthcare and impact India's growing obesity crisis.

Israel-India Strengthen Ties Against Terrorism Threat

Israel's Foreign Minister Eli Cohen emphasizes growing strategic partnership with India, highlighting shared terrorism threats and expanding cooperation in defense, technology, and agriculture during crucial diplomatic meetings.

FDA Approves Oral Weight Loss Drug Rybelsus

Breaking news: US FDA approves Rybelsus, the groundbreaking oral weight loss medication that mimics popular injection drugs. Discover how this pill could revolutionise obesity treatment in India and worldwide.

Page 1 of 2